sugammadex (bridion) Report issue

Small molecule Approved FDA First in Class Priority Review FDA

Active Ingredient History

  • Now
Sugammadex (ORG 25969) is a cyclodextrin derivative was synthesized as synthetic receptor (or host molecule) for neuromuscular blockers (rocuronium and vecuronium). It forms a complex with the neuromuscular blocking agents rocuronium and vecuronium, and it reduces the amount of neuromuscular blocking agent available to bind to nicotinic cholinergic receptors in the neuromuscular junction. This results in the reversal of neuromuscular blockade induced by rocuronium and vecuronium. The clinical use of sugammadex promises to eliminate many of the shortcomings in current anesthetic practice with regard to antagonism of rocuronium and other aminosteroid muscle relaxants. Sugammadex is indicated for the reversal of neuromuscular blockade induced by rocuronium bromide and vecuronium bromide in adults undergoing surgery.   NCATS

  • SMILES: O[C@@H]1[C@@H](O)[C@@H]2O[C@H]3O[C@H](CSCCC(=O)O)[C@@H](O[C@H]4O[C@H](CSCCC(=O)O)[C@@H](O[C@H]5O[C@H](CSCCC(=O)O)[C@@H](O[C@H]6O[C@H](CSCCC(=O)O)[C@@H](O[C@H]7O[C@H](CSCCC(=O)O)[C@@H](O[C@H]8O[C@H](CSCCC(=O)O)[C@@H](O[C@H]9O[C@H](CSCCC(=O)O)[C@@H](O[C@H]1O[C@@H]2CSCCC(=O)O)[C@H](O)[C@H]9O)[C@H](O)[C@H]8O)[C@H](O)[C@H]7O)[C@H](O)C6O)[C@H](O)[C@H]5O)[C@H](O)[C@H]4O)[C@H](O)[C@H]3O
  • Mol. Mass: 2002.18
  • ALogP: Missing data
  • ChEMBL Molecules:
More Chemistry
  • Mechanisms of Action:
  • Multi-specific: Missing data
  • Black Box: No
  • Availability: Prescription Only
  • Delivery Methods: Parenteral
  • Pro Drug: No

Drug Pricing (per unit)

United States

$72.7410 - $176.3720
More Pricing Detail

Note: This drug pricing data is preliminary, incomplete, and may contain errors.

6-perdeoxy-6-per(2-carboxyethyl)thio-gamma-cyclodextrin sodium salt | bridion | org 25969 | org-25969 | sugammadex | sugammadex sodium | suggamadex


Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue